The Journal of Molecular Diagnostics
,
Association for Molecular Pathology (AMP), co-sponsored by the American Society
for Investigative Pathology (ASIP), seeks to publish high-quality original papers on
scientific advances in the field of molecular diagnostics,
the translation and
validation of molecular discoveries in medicine into the clinical diagnostic setting,
and the description and application
of technical advances in the field of molecular
diagnostic medicine. The editors welcome for review manuscripts that contain:
novel discoveries
with direct application to clinical diagnostics or clinicopathologic
correlations including studies in oncology, infectious diseases,
inherited diseases,
predisposition to disease, or the description of polymorphisms linked to disease
states or normal variations; the
application of diagnostic methodologies in clinical
trials; or the development of new or improved molecular methods for diagnostic or
monitoring of disease predisposition.
Manuscript Categories.
In addition to Regular Articles, the Journal
also
publishes Reviews, Commentaries and Special Articles solicited by the Editorin-
Chief, as well as AMP meeting abstracts
and other articles of interest to the
membership of AMP. Authors who wish to publish a Review should send their
curriculum vitae
along with an outline of the proposed article for prior approval by
the Editor-in-Chief. Reviews should have a maximum of 5,000 words,
75
references, and 4 tables or figures (at least one of which is mechanistic).
The Journal features two special peer-reviewed
sections in addition to full-length
original research articles. Consultations in Molecular Diagnostics features
short, case-directed
articles that illustrate a classic principle, a difficult
interpretation, or a new approach in molecular diagnostics. Submissions to
this
category should include a case report and discussion of how the use of molecular
diagnostics led to resolution of the case. Technical
Advances are intended to
report breakthroughs in methodology or analytical tools applied to molecular
diagnostics. Submissions to
this category should include a detailed description of
the methodological design and discussion of how this technique improves the
practice
of molecular diagnostics.
Effective January 2011, the Journal will no
longer publish the section known as Consultations
in Molecular Diagnostics
(also known as case reports). Under rare circumstances, case reports with
exceptionally high scientific value
may be published as Regular Articles or
Technical Advances.
Review Process.
The Editors perform an initial
evaluation on all submissions to
determine whether they believe the manuscript will achieve a sufficient priority score
to warrant publication.
Priority is determined by the Editors' assessment of the
manuscript relative to other papers being considered. The aim is that expeditious
treatment will enable authors to submit their manuscript elsewhere as soon as
possible without suffering unnecessary delays. For manuscripts
accepted for
external review, the Editor-in-Chief assigns manuscripts to Associate Editors
according to their expertise. The Associate
Editor will solicit reviewers (typically, two
external reviews are sought). Authors are encouraged to identify up to five potential
reviewers.
Authors may also request that specific reviewers not be used due to prior
collaborations, known conflicts of interest, or direct competition.
The Editors will
make every effort to respect requests that are well-founded; however, the Editors do
have the authority to utilize such
a reviewer if it is necessary for expert peer review.
It is the practice of the Journal to conduct a blinded peer-review process.
The peerreview
process is kept completely confidential; it is considered a violation of this
confidentiality for authors to identify
or attempt to communicate directly with peer
reviewers or Associate Editors regarding their manuscript. The reviewer comments
and Associate
Editor's recommendation are evaluated by the Editor-in-Chief for
disposition and transmittal to the authors. Every effort is made to
complete the
review process within 35 days of the date received.
Review Decisions.
Only a portion of manuscripts will
be accepted for
publication. A number of worthy manuscripts will be rejected based on priority. TheJournal will advise authors
whether the manuscript is accepted, acceptable with
revisions, rejected but encourage resubmission (after major revision), or rejected.
A
manuscript may be returned to the authors without outside review if the Editors find
it inappropriate for publication in this Journal.
Appeals (rebuttals) to editorial
decisions must be submitted within 60 days to be considered.
Journal Scientific Integrity
Policy.
The Journal has developed principles for
defining scientific misconduct as well as procedures for handling
such matters.
General guidelines are described below; detailed information can be viewed
here. To report suspected misconduct
relating to authors, reviewers, or Editors, send written complaint to the Editorial
Office at The Journal of Molecular Diagnostics, 9650 Rockville Pike, Bethesda,
Maryland, USA 20814-3993 or jmd@asip.org.
Issues relating to staff conduct
should be directed to the AMP Executive Officer at the Association for Molecular
Pathology, 9650 Rockville
Pike, Bethesda, Maryland, USA 20814-3993 ormesobel@asip.org.
Author Conduct.
Authorship is defined
as 1) substantial contributions to
conception and design, or acquisition of data, or analysis and interpretation of data;
2) drafting
the manuscript or revising it critically for important intellectual content;
and 3) final approval of the version to be published. Authors
should meet conditions
1, 2, and 3. When submitting a manuscript to the Journal, the corresponding author
takes responsibility
on behalf of all authors for the authorship, authenticity and
integrity of the research being reported. Authors should take special care
that
manuscripts submitted to the Journal are prepared in accordance with the Uniform
Requirements for Manuscripts Submitted
to Biomedical Journals (see
http://www.icmje.org); in particular the ethical considerations regarding authorship,
conflicts
of interest, redundant publication and treatment and confidentiality of
research subjects should be carefully adhered to. Additionally,
the Journal takes
great care to secure the confidentiality and integrity of the peer-review process; it is
considered a violation
of this confidentiality for authors to identify or attempt to
communicate directly with peer reviewers or Associate Editors regarding
their
manuscript. The Editors will consider any deliberate ethical violation in either the
reported research or the manuscript preparation
and review to be actionable
misconduct, the potential results of which may be manuscript rejection or public
article retraction, reporting
of conduct to the authors' governing institutions, and/or
the denial to consider any future submissions to the Journal. Willful
misconduct
does not include incidents of honest misjudgment or inadvertent error. Detailed
information regarding possible misconduct
can be found in the Journal Scientific
Integrity Policy.
Manuscript Submission.
Manuscripts should be submitted online via the
Rapid Review
system (
http://www.rapidreview.com/ASIP2/CALogon.jsp). Detailed
instructions on preparing and submitting files can be found
on the author
submission website at the above URL. Authors having difficulty submitting files
online should complete the online submission
form on Rapid Review to receive the
assigned manuscript number. With the manuscript number clearly noted, electronic
files (manuscript
text, figures, and tables) should be emailed to the Editorial Office
at jmd@asip.org or sent on disk by mail to: Timothy
J. O'Leary, M.D., Ph.D.,
Editor-in-Chief, The Journal of Molecular Diagnostics, 9650 Rockville Pike,
Bethesda, Maryland, USA
20814-3993. The cover letter must state any conflicts of
interest (both financial and personal), affirm that the manuscript has not
been
published previously and is not being considered concurrently by another
publication, and affirm that all authors and acknowledged
contributors have read
and approved the manuscript. Submissions will be ineligible for review if previously
published in any form (print
or online) other than as an abstract. This includes any
public posting of raw manuscripts or pre-reviewed material.
A non-refundable
manuscript processing fee of U.S. $50 is required with
submission. This fee should be paid electronically at the time of submission.
Manuscripts arising from research in developing countries may be eligible for waiver
of the submission fee only if all authors are located
in a qualifying country (waiver
must be applied for at time of submission; see list
of eligible countries). Otherwise, manuscript submission
fees will not be waived.
Manuscript Preparation.
Manuscripts
should be prepared in the style of theJournal and in accordance with The Uniform Requirements for Manuscripts
Submitted to
Biomedical Journals (see
http://www.icmje.org). The preferred file
format for text is MS Word. Standard abbreviations can
be found in the CSE Style
Manual (7th ed., 2006). All pages of the manuscript should be double-spaced and
numbered (including references,
tables and figure legends). Other formatting
specifications (eg, font size and type, margin settings, etc.) are left to the authors'
discretion, as papers accepted for publication will be reformatted according to the
print specifications of the Journal. Manuscripts
not prepared in accordance with the
submission guidelines detailed below may be returned to the authors. Authors are
encouraged to include
a list of nonstandard abbreviations to aid reviewers;
however, the Journal does not publish abbreviations or keywords as part
of the final
article. In addition, authors should be ready to comply with Editors' requests for
copies of any similar works in preparation,
copies of cited manuscripts that are
submitted or in press, and/or supporting manuscript data (eg, data not shown, but
summarized in
the manuscript) that may aid the review process.
Title Page.
The title page must include a concise title accurately
reflecting the
findings of the work; full names (not initials) of all authors; department, institution
and address where the research
was performed; number of text pages, tables and
figures; a short running head (40 characters or less); grant numbers and sources of
support;
name, address, phone, fax, and email of the corresponding author; and
name and address of author who should receive reprint requests.
If an author
changes employment after the study was performed, the new affiliation information
for that author should be included as
a footnote. Any affiliations (eg, employment,
consultancies, board membership, stock ownership, funding, honoraria, expert
testimony,
patents or royalties, travel reimbursements, industry-supplied free
reagents, etc) with any organization or entity having a direct financial
or personal
interest in the subject matter or materials discussed in the article should also be
clearly stated.
Abstract.
An abstract of 220 words or less should be prepared on a separate
sheet and should be intelligible to the general reader without reference
to the text.
The abstract should clearly summarize the background, methodology, results, and
significance of the study. Abbreviations
and citations should be avoided.
Text.
The remaining sections of the text, which may include Introduction, Materials
and Methods, Case Report (for Consultations in Molecular Diagnostics), Results,
Discussion, and Acknowledgments (in this order), need
not begin on new pages.
Commonly-abbreviated terms should be spelled out in their first occurrence and
then may be referenced in abbreviation
through the remainder of the manuscript.
Consult the Human Genome Organisation Gene Nomenclature Committee website
(
http://www.genenames.org/)
for gene names and symbols. For a complete list of
other approved nomenclature organizations (eg, bacteria, viruses, mice), please
contact
the Editorial Office.
For Materials and Methods, authors should describe experimental and statistical
methods in enough detail
that other researchers can replicate results and evaluate
claims. In general, inclusion of method or reagent details as supplementary
material
is not acceptable. The sequences of oligonucleotides, if not previously published,
should be provided. Novel DNA or protein
sequences should be deposited to an
appropriate database (eg, Genbank, EMBL, SWISS-PROT), with the accession
numbers included in the
manuscript. When providing supplier information for
materials sources, company name and location (city and state, or city and country)
should be provided. Website references to company information are not permitted.
All novel materials and the procedures to prepare them
should be described in
sufficient detail to allow their reproduction (eg, DNA constructs, analytical software).
Materials that are approved
for investigational-use only should be clearly indicated.
Special care should be taken to assure that statistical methods are appropriate.
A
careful power analysis undertaken at the beginning of work can help assure the
significance of study findings. "Discrepant Analysis"
is regarded as statistically
biased, and should not be employed for assessment of assay sensitivity and
specificity. Reports of assay
sensitivity and specificity should include appropriately
calculated confidence intervals.
Publication in the Journal implies
that the authors agree, upon reasonable request,
to share any materials or data that are integral to the results presented in the
article,
including whatever would be necessary for a skilled investigator to verify or
replicate the claims. Authors must disclose upon submission
any restrictions on the
availability of materials or information, such as for patented or dual-purpose
materials.
Reporting guidelines
for specific study designs (eg, randomized controlled trials)
can be found in the Uniform Requirements for Manuscripts Submitted to Biomedical
Journals (see
http://www.icmje.org). Authors must affirm that the research protocol
was approved by the appropriate institutional
review boards or ethics committees
for human (including use of human cells or tissues) or animal experiments and that
all human subjects
provided appropriate informed consent and/or that regulations
concerning the use of animals in research were adhered to. If race/ethnicity
is
reported, authors should state who determined race/ethnicity, how the options were
defined, and why race/ethnicity was important in
the study. Authors should be
prepared to provide study protocol number(s) if requested.
Authors should obtain permission from all
individuals named (by full name) in theAcknowledgments who contributed substantially to the work reported (eg, data
collection,
analysis, or writing/editing assistance) but did not fulfill the authorship
criteria. Likewise, authors should receive permission from
all individuals named as
sources for personal communication or unpublished data. Such permissions should
be affirmed by the corresponding
author in the cover letter.
References.
References should begin on a new page, be double-spaced and
numbered in order
of citation in the text, including citations in tables and figure
legends. Complete author citation is required (use of "et al" is not
acceptable).
References should conform to the style of the Journal. Examples follow:
Journals: Cecena G, Wen F, Cardiff
RD, Oshima RG: Differential sensitivity of
mouse epithelial tissues to the polyomavirus middle T oncogene. Am J Pathol 2006,
168:310-320
Books: Fishman AP: Pulmonary Hypertension and Cor Pulmonale. Pulmonary
Diseases and Disorders. Edited by Fishman AP. New York,
McGraw-Hill, 1988, pp.
999-1048
In press: To be used only for papers accepted for publication. Cite as for journal
with (in
press) in place of volume and page numbers. Include digital object identifier
(doi) when available for online early publications.
Submitted papers/unpublished data: Cite in text only.
Web sites: Cite in text only. See Data Supplements section
below for proper use of
web site references. Use the doi when available. Include the name of the institution
sponsoring the web site,
URL address with direct linkage to the referenced
information, and date of access.
Tables.
Tables should be typed
double-spaced and submitted after the main text
on separate pages, as part of the manuscript. The preferred file format for Tables is
MS Word; figure file formats (including those embedded in the text) are
unacceptable. Tables should be black and white text only and
should not include
figures or other non-typeset images. Color or gray shading is not permitted.
Emphasis may be represented by bold,
italics, and underlining. Table footnotes
should use the following sequential symbols: *,†, ‡, §, ||, ¶;
these may be doubled
up if needed. All symbols and abbreviations in the table should be defined in the
footnotes.
Figures.
Authors should give considerable care in preparing figures. Resolution
and quality of submitted images is the responsibility of the author;
as a routine, theJournal does not provide figure enhancement services. Images (such as graphs
and schematics) should have a
white background; color, black, or gray is generally
unacceptable. Authors are encouraged to carefully consider whether bar or line
graphs
should be submitted in grayscale or color, paying special attention to the
ability of a reader to distinguish between different data
points. Figures may consist
of multiple related panels (labeled A, B, C, etc.) described under one figure legend.
Each figure (with all
of its related panels) should be arranged on a single page as it
should appear in final publication. Figure labels should appear in the
upper left
corner as uppercase letters; refrain from using sub-labels (Aa, Ab, Ai, Aii, A1, A2,
etc) or titles for each panel label;
panels should be labeled chronologically from left
to right. Figure panels submitted on separate pages will be arranged at the
publisher's
discretion. If figures are to be published in black and white, they should
be submitted for review in black and white. When preparing
composite figures, the
front side of individual parts should be clearly and properly labeled. Figures should
be sized to fit one column
(8 cm) or two columns (17 cm). Maximum page length is
22.5 cm. Figures deviating from these dimensions will be sized at the publisher's
discretion. Unwanted background material should be excluded, and edges should
be straight.
Preparation of Images (Ethics):
Taking photographs under varied fields of view,
light intensity, magnifications, or contrast conditions without disclosing that the data
are not unique to the present study constitutes suspect scientific conduct. Further,
unless serial sections are used, the publication
of identical-appearing images
labeled with different staining techniques in different papers raises legitimate
questions. Finally, reuse
of one's data (ie, "self-plagiarism") is a copyright violation if
the authors signed over copyright to the publisher; the reuse of such
copyrighted
images is at the sole discretion of the publisher, with proper attribution of the
original publication a requirement of reuse.
No specific feature within an image may
be enhanced, obscured, moved, removed, or introduced. The grouping of images
from different parts
of the same gel or blot, or from different gels or blots, fields, or
exposures must be made explicit by the arrangement of the figure
(eg, using
dividing lines) and in the figure legend. Adjustments of brightness, contrast, or color
balance are acceptable only if they
are applied to the whole image, whether
experimental or control image, and as long as they do not obscure or eliminate any
information
present in the original (Portions adapted with permission from the JCB).
Any evidence of inappropriate manipulation may prompt the Editors
to request an
explanation and access to original data, which the authors must make available.
Information can be found in the Journal Scientific Integrity Policy.
Digital Art: Digital figure files are required
for submission. The Journal of
Molecular Diagnostics' requirement for color images is RGB (Red, Green, Blue)
color mode. Images
submitted in RGB will retain the vivid reds, greens, and blues of
the original digital files for online publication. Authors should therefore
submit all
figures (for both new and revised manuscripts) in the RGB color mode. The
preferred file formats for digital figures are PDF,
TIFF, and EPS. For detailed
instruction on preparing digital art for submission or production, visit
http://cpc.cadmus.com/da/
or contact the Editorial Office (jmd@asip.org).
Figure Legends.
Figure legends should be submitted
as part of the manuscript
(separate from the figure files) and should describe any staining method and
degree of magnification. If the
exact scale is critical, scale bars should be used on
the photograph and specified in the legend. Figure legends should adequately
describe
all descriptors: arrows, arrowheads, scale bars, insets, asterisks,
boxes/circles/etc in line graphs, and any other notations. Descriptive
text, rather
than graphics inserted into the text, should be used when possible (eg, closed
circles, open boxes, hatched bars, etc);
alternatively, a legend key should be
included in the figure. Statistical significance (eg, P values) should be clearly
defined
by asterisks (*, **, ***) or by other sequential symbols: *,†, ‡, §, ||, ¶; these
may be doubled up if
needed. All abbreviations should also be defined.
Data Supplements and Non-Traditional Media.
Figures and tables that
are critical to the evaluation and understanding of the research presented, but
which cannot be accommodated via the print medium (eg,
video), will be considered
part of the manuscript submission and will be published on the Journal website if
the manuscript
is accepted. Supplemental figures, tables, and legends should be
prepared as above. Supplemental material published on the Journal
website is
subject to the same copyright as applies to the printed article. Online data will
remain associated with its article and is
not subject to any modifications or updates
after publication. Authors of accepted manuscripts will be charged $50 per
supplemental
data file to be published on the Journal website (up to 1MB; files over
1MB will be charged an additional $50 per megabyte).
Authors are therefore
encouraged to minimize the size of their supplemental data files.
Complex data sets such as microarray data
and gene sequences should be
deposited in a reliable public archive. Microarray repositories should comply with
the Minimum Information
About a Microarray Experiment (MIAME guidelines).
Examples include
Gene Expression Omnibus and Array
Express. Tissue microarray data exchange
specifications can be found at
http://www.biomedcentral.com/1472-6947/3/5.
Otherwise, the data may be published as supplemental data on the Journal's
website (
http://jmd.amjpathol.org).
Other materials that are not required to understand and evaluate the article may be
stored on an institutional website and referenced
as a URL within the manuscript
text. In this case, the authors must assume responsibility for maintaining a live,
unrestricted link to
the material from the URL published within the article, in
perpetuity. Failure to maintain a live, unrestricted link may result in retraction
of the
article by the Editors. Material that has been published previously (print or online) is
not acceptable for posting as supplementary
data. Instead, the appropriate
reference(s) to the original publication should be made in the text and references.
The Editors will make
the final determination as to whether a given data set is
essential to the manuscript and whether they will require publication of the
material
on the Journal website. Failure to relinquish required materials for online publication
can result in the reversal
of a manuscript's acceptance.
Copyright.
Copyright of published manuscripts is held by the Association for
Molecular
Pathology and the American Society for Investigative Pathology, which
must receive the assignment of copyright from the authors of accepted
manuscripts. For US government employees, the above assignment applies only
to the extent allowed by law. See
http://www.asip.org/pubs/jmdrights.pdf
for details.
Through The Journal of Molecular Diagnostics' affiliation with PubMed Central
(PMC), the Journal deposits
all final published articles in PMC, to be made
available to the public twelve months after final print publication. Publishing in the
JMD automatically places authors in compliance with the NIH Public Access Policy
(see
http://publicaccess.nih.gov/submit_process.htm,
Submission Method A).
Authors therefore should NOT complete a separate deposit of their material but will
be contacted by PubMed Central
for grant verification once the article has been
received by the PMC article system. For information on how to cite articles in NIH
grant
applications, please visit
http://www.asip.org/pubs/AuthorNotice.htm.
Contact the Editorial Office regarding permission
to deposit manuscripts in other
government-sponsored repositories in cases where The Journal of Molecular
Diagnostics does not
have a system in place to automatically deposit materials on
behalf of their authors. Deposit of accepted or published manuscripts in
any non-JMD repository without prior permission by the Journal is a violation of copyright.
Embargo Policy.
All information regarding the content of submitted or accepted
manuscripts is strictly confidential. Information contained in or about
accepted
articles cannot appear in print, audio, video, or digital form or be released by the
news media until the Journal embargo
date has passed, not to exceed the
publication date of the article. For detailed information on embargo release dates or
for news media
requests for preprint copies of specific articles, contact the Editorial
Office at 301-634-7959 or jmd@asip.org.
Financial
Disclosure and Conflicts of Interest.
All authors must disclose
any current or former affiliations (eg, employment, consultancies,
board
membership, stock ownership, funding, honoraria, expert testimony, patents or
royalties, travel reimbursements, industry-supplied
free reagents, etc) with any
organization or entity having a direct financial or personal interest in the subject
matter or materials
discussed in the article. Authors should err on the side of full
disclosure and should contact the Editorial Office if they have questions
or
concerns. This information should be provided at the time of submission and
reiterated as part of copyright assignment. Failure to
do so may result in manuscript
rejection or editorial retraction of the article. Further information can be found in the
Journal Scientific Integrity Policy.
Upon manuscript acceptance, all coauthors will be instructed to
formally disclose all
potential conflicts.
Publication Charges
Figure and Table Charges: Authors will be
charged $550 per color figure, $50 per
black & white or grayscale figure, and $50 per composed table, per printed
page
(ie, figures or tables necessitating more than one printed page will incur an
additional charge). Corresponding authors of published
manuscripts who are
current, dues-paying regular members of ASIP at the time of submission will receive
for ASIP members.
Page
Charges: Authors will be charged $65 per printed page. Manuscripts arising
from research in developing countries may be eligible
for waiver of publication
charges only if all authors are located in a qualifying
country. Otherwise, page charges will not
be waived, except for solicited editorials.
Approval of Fees and Invoicing:
A summary of publication charges (figures,
tables, and supplemental data) will be presented to the corresponding author of
accepted manuscripts
for approval prior to publication; final page charges cannot
be determined until final publication. Color figure charges will not be
waived, but
color figures may be published in black and white, pending editorial approval.
Requests for black and white figure publication
must be made prior to execution of
the publication charge approval form to avoid color charges. A final invoice will be
presented immediately
after publication; full payment is expected at that time.
Open Choice.
In addition to publication charges outlined
above, authors may
elect to participate in the Journal's Open Choice program. Articles published under
Open Choice will become immediately
accessible on the Journal website upon
publication, without the twelve-month subscriber-only access delay. Authors wishing
to participate
should contact the Editorial Office following manuscript acceptance.
All copyright restrictions regarding reuse still apply. Cost to
participate is $1500,
which must be received before article restriction is lifted.
Reprints.
Reprints should
be ordered when page proofs are returned; an order
form is included with the proofs. Late reprint orders may result in additional fees.
There is no extra charge for color reprints. Author reprints will be supplied in CMYK
color mode because it is a printed medium, but
electronic reprints will be supplied in
RGB color mode for visualization on screen. Each author will receive one
complimentary electronic
(secure PDF) reprints for distribution at their discretion.
Additional electronic reprints can be ordered at the time page proofs are
returned or
at a later date. No hardcopy complimentary reprints are provided by the publisher.
Proofs.
The corresponding
author will be contacted by email once proofs are
ready and will be directed to download electronic proofs from a secure website.
Electronic
page proofs will be provided in RGB, thus reflecting the online quality.
Image files will be converted to CMYK for the printed journal;
all images published
online will be in RGB. Full instructions on completing proof corrections will be
provided with the downloaded proof.
The author should check the proofs carefully,
mark any printer's errors, and answer queries as requested. Author changes should
be kept
to a minimum. Proof corrections and replacement figures (if any) must be
returned within 24 hours to avoid any delay in publication.
Cover Figure.
The cover figure is selected by the Editors from illustrations
appearing in the issue. Authors are encouraged
to suggest a figure for
consideration, or include an additional cover figure submission along with their
manuscript submission. Cover
figures are published at no charge; cover reprints
are available as cover stock reprints or posters (no complimentary cover reprints
are provided by the publisher).
Editorial Communications.
All correspondence concerning editorial matters
should be
addressed to the Editor-in-Chief at The Journal of Molecular
Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993,
faxed to
301-634-7961, or emailed to jmd@asip.org. Appeals (rebuttals) to editorial
decisions must be submitted within
60 days to be considered. Letters to the Editor
will be printed at the Editors' discretion in the Correspondence section.
Corrections
are published upon request and after editorial review. Retractions are
published upon request of authors or their institutions
and may also be published by
the Journal following a determination of scientific misconduct. Notes of Concern
are published in
response to editorial concerns relating to scientific or publishing
misconduct by authors or reviewers or to alert the scientific community
of an
ongoing investigation.
